Objective-Therapeutic angiogenesis is a promising strategy for treating ischemia. Our previous work showed that endogenous endothelial tissue factor (TF) expression induces intracrine signaling and switches-on angiogenesis in microvascular endothelial cells (mECs). We have hypothesized that activated mECs could exert a further paracrine regulation through the release of TF-rich microvascular endothelial microparticles (mEMPs) and induce neovascularization of ischemic tissues. Approach and Results-Here, we describe for the first time that activated mECs are able to induce reparative neovascularization in ischemic zones by releasing TF-rich microparticles. We show in vitro and in vivo that mEMPs released by both wildtype and TF-upregulated-mECs induce angiogenesis and collateral vessel formation, whereas TF-poor mEMPs derived from TF-silenced mECs are not able to trigger angiogenesis. Isolated TF-bearing mEMPs delivered to nonperfused adductor muscles in a murine hindlimb ischemia model enhance collateral flow and capillary formation evidenced by MRI. TF-bearing mEMPs increase angiogenesis operating via paracrine regulation of neighboring endothelial cells, signaling through the β1-integrin pathway Rac1-ERK1/2-ETS1 and triggering CCL2 (chemokine [C-C motif] ligand 2) production to form new and competent mature neovessels.
A ngiogenesis plays a key role in physiological processes, including embryonic development and wound repair, as well as in various pathologies such as ischemic diseases, cancer, diabetic retinopathy, or chronic inflammation including atherosclerosis. 1 Angiogenesis is an active process that depends on a delicate interplay between endothelial cells (ECs) and smooth muscle cells (SMCs). 2 Modulation of angiogenesis represents a potential therapeutic tool against a large number of diseases. An increased neovascularization leading to wound healing and ischemic injury repair is a much searched therapeutic goal. Recent studies support the concept of a proangiogenic effect of microparticles, depending on their composition and concentration. [3] [4] [5] [6] [7] High amounts of microparticles were detected in mouse after hindlimb ischemia, and their increased levels were associated to restoring the consequences of arterial occlusion and tissue ischemia by promoting postischemic neovascularization. 8 Microparticles are 0.1-to 1-μm plasma membrane-derived vesicles shed from stimulated cells. 9 ECs can release microparticles when they are activated. Endothelial-derived microparticles (EMPs) are subcellular fragments of the EC lipid bilayer. EMPs that are release in relatively low numbers in physiological conditions are increasingly released on cell activation. [10] [11] [12] EMPs harbor membrane proteins and intracellular components involved in cell signaling that are characteristic of the original parent cell. Microparticles from activated ECs cells are known to carry tissue factor (TF), and their procoagulant properties during disease have been characterized. [13] [14] [15] TF is a low-molecular weight glycoprotein that initiates the extrinsic clotting cascade and is considered a major regulator of arterial thrombogenicity. 16, 17 In addition, during the past decades, TF has also shown to be involved in intracellular signaling pathways in cell function regulation (ie, proliferation, 18 migration, 19, 20 gene expression, 21 and mature microvessel formation). 22, 23 Our previous work showed that proangiogenic microvascular ECs (mECs) regulate intracellular TF expression and by intracrine AKT-ETS signaling induce chemokine (C-C motif) ligand 2 (CCL2) expression and secretion to recruit SMC toward the mECs to form mature neovessels. 23, 24 TF is found in 2 different molecular forms: full-length TF (flTF), an integral membrane protein; and alternatively spliced TF, a protein that lacks a transmembrane domain and is secreted in a soluble form. 25 Both forms have been associated with the angiogenic processes. However, TF can also be released from the cell membrane in the form of microparticles, which constitute a pool of circulating TF. 26, 27 Increased number of TF-bearing microparticles resulting from vesicle release from platelets and other blood cells or tumor cells and their procoagulant activity has been extensively documented in several vascular diseases. [28] [29] [30] Despite a growing interest in MPs as inducers of angiogenesis, little is known on the effects of TF-bearing mECs-derived microparticles (mEMPs) on ischemic tissue reperfusion. We hypothesized that phenotypic changes in mECs may induce release of mEMPs with functional angiogenic activity in ischemic tissue reperfusion. Our data show that TF released from activated mECs in the form of microparticles interact via paracrine signaling with other mECs operating through a β1-integrin fashion and induce neovessel and collateral vessel formation in ischemic zones. Furthermore, we show that while endogenous TF-intracrine signaling is processed through v-akt murine thymoma viral oncogene homolog 1 (AKT) pathway, TF-bearing mEMPs (exogenous TF) signals through β1-integrin engagement.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Microvascular EC Forming Tube-Like Structures Release TF-Bearing Endothelial Microparticles
In contrast to monocytes or tumor cells, mECs do not constitutively express TF and release microparticles spontaneously; however, after stimulation, TF may be released from cells in form of microparticles. First, we studied whether during tubelike formation, activated mECs release TF-rich microparticles. Results showed that, in quiescent mECs (resting cells in culture), intracellular TF levels were very low and localized around the cell nucleus ( Figure 1A ). However, when mECs were stimulated to migrate by scratch lesions in cell monolayers, TF expression increased at border edges of cells and in cell lamellipodia in the cell migratory front. Living cell membrane dye and confocal microscopy analysis revealed that angiotube-forming cells spontaneously shed membrane vesicles from the cell plasma membrane. Formed and released vesicles had a roughly spherical shape and varying size from 0.5 to 1 μm ( Figure 1B ). To study whether these vesicles contain TF, we analyzed the endothelial conditioned media of human dermal endothelial cell and human microvascular endothelial cell-1 either in quiescent state, in migrating phenotype, or in forming tube-like structures phenotype (cultured on matrigel for 18 hours). As shown in Figure 1C , the number of mEMPs positive for TF analyzed by flow cytometry was much higher in the endothelial conditioned media of angiotube-forming cells than in the endothelial conditioned media of quiescent cells. Similar results were obtained using human microvascular endothelial cell-1 ( Figure IIA in the online-only Data Supplement).
These results show that although release of TF-bearing mEMPs is limited in static quiescent mECs, it is highly activated in angiotube-forming mECs.
Effect of TF-Bearing mEMPs in Microvascular EC Tube-Like Formation
Previously, we demonstrated that in mECs endogenous TF contributes to angiogenic processes. 22 Here, we investigated whether the released TF-rich mEMPs were able to induce endothelial angiotube formation. TF-rich microparticles (TF + mEMPs) were obtained from migrating TF overexpressing cells to have high amounts of TF ( Figure IIB in the online-only Data Supplement). Cells were cultured on 3-dimensional (3D) basement membrane and incubated with TF + mEMPs (3.5×10 7 mEMPs containing 100 pmol/L of TF). We observed that TF + mEMPs induced a complex network of angiotubes and with many branching points (Figure 2A and 2B). This effect was not observed in mECs exposed to TF-poor mEPs (TF − mEMPs; 3.5×10 7 mEMPs containing <2 pmol/L of TF). TF − mEMPs were obtained from TF-silenced mECs that were forced to migrate for 48 hours to stimulate microparticles release. Silencing TF gene (TF siRNA) induced inhibition of angiotube formation that was partially rescued by addition of TF + mEMPs, but not by the addition of TF − mEMPs. Control cells were always treated with random siRNA as a proper control. TF-silenced cells released negligible amounts of mEMPs positive for TF, which by flow cytometry were positive for annexin V but negative for TF ( Figure IIC in the online-only Data Supplement). Moreover, confocal microscopy of mECs forming tube-like structures (red) and labeled TF + mEMPs (green) showed that TF + mEMPs are bound to the mEC surface ( Figure 2C and 2D).
TF + mEMPs Ligate β1-Integrin on mECs Surfaces and Induce Signaling
Because exogenous TF has been shown to interact with integrins, 31 and it has been demonstrated that microparticle-TF induce EC proliferation by β1-integrin interaction, 32 the possibility that TF + mEMPs-induced angiotube formation was mediated by the interaction with β1-integrin in mECs was next examined. By flow cytometry, we studied whether TF + mEMPs to ligate mECs through β1-integrin. Microvascular ECs pretreated with β1integrin-blocking antibody were treated with TF + mEMPs, and the number of cells positive for GFP (green fluorescent protein)-TF + mEMPs was analyzed. Pretreatment of mECs with the β1integrin-blocking antibody inhibited TF + mEMPs binding to mECs ( Figure 2E ). These results were corroborated by adhesion studies, in which tissue culture plates were coated with collagen 1%, as positive controls, or TF + mEMPs after which mECs were seeded. Figure 2F shows that the mECs bound to TF + mEMP-coated plates in a β1-integrin-dependent fashion because β1-blocking antibodies significantly reduced adhesion.
Incubation of mECs with TF + mEMPs increased TF protein levels in mEC-forming tubes; however, previous incubation of mECs with β1-integrin-blocking antibody suppressed the increased TF levels ( Figure 2G ). Increased TF levels were because of TF transfer from TF + mEMPs ( Figure III Previously, we had demonstrated that TF-intracrine signaling in mECs induces tube formation and stabilization through AKT-ETS1 activation and CCL2 expression. 23 Here, we investigated whether the TF transported by mEMPs and ligated to mECs through integrins was able to induce similar signaling. Result showed that TF from TF + mEMPs was able to trigger signaling through Rac1, ERK1/2, ETS1 activation, and finally increase CCL2 protein levels ( Figure 2G ). To confirm these results and because CCL2 is a secreted protein, we analyzed CCL2 concentration in mEC culture supernatants. CCL2 concentration was significantly increased in mECs exposed to TF + mEMPs (825.3±57 versus 467.25±12.6 pg/mL without TF + mEMPs). In agreement with the Western blot results, CCL2 secreted levels were significantly reduced in cells preincubated with β1-integrin-blocking antibody (392±23 pg/mL; Figure 2H ). As shown in Figure IV in the online-only Data Supplement, TF + mEMPs induce β1-integrin mRNA expression in mECs (>50%). Even in Figure 3 . Tissue factor (TF)+microvascular endothelial cell micropaticles (mEMPs) induce angiogenesis. Aortic segments from nude mice were implanted into matrigel supplemented with: solvent control (PBS); vascular endothelial growth factor/fibroblast growth factor 2 (basic) (VEGF/bFGF) (50 ng/mL each); TF + mEMPs (100 pmol/L); recombinant TF (100 pmol/L); β1-integrin antibody; β1-integrin antibody with VEGF/bFGF (50 ng/mL each); β1-integrin antibody with TF + EMPs; and β1-integrin antibody with recombinant TF. Outgrowing sprouts were visualized and counted on day 4. Images are representative from 4 independent experiments. Sprouts were counted and represented as the average of area covered by sprouts from 4 independent experiments. Values are mean±SEM. Statistical analysis was performed by ANOVA followed by Tukey post hoc test (***P<0.001).
β1-integrin-silenced mECs, the exposure of mECs to TF + mEMPs induces de novo synthesis of β1-integrin mRNA. These results indicate that extracellular TF needs β1-integrin engagement before triggering signaling, while as we showed before endogenous TF signals via intracrine pathways through AKT.
To exclude any possible thrombin effects in the process, we treated cells with hirudin. Results show that CCL2 expression was unaffected ( Figure V in the online-only Data Supplement).
To investigate whether PAR2 was involved in TF + mEMPinduced signaling, we silenced PAR2 in mECs. In PAR2-silenced cells, TF + mEMPs triggered signaling was unaffected ( Figure VI in the online-only Data Supplement). These results indicate that interaction between mECs and TF + mEMP does not require PAR2.
TF + mEMPs Induce Vessel Growth Ex Vivo and In Vivo
An ex vivo aortic sprouting model was used to test the angiogenic effects of TF transported in mEMPs. Segments of aortas isolated from nude mice were implanted in matrigel plates containing: control buffer, vascular endothelial growth factor/ fibroblast growth factor 2 (basic) (VEGF/bFGF), TF + mEMPs, and recombinant TF protein, as a positive control. Figure 3 shows that VEGF/bFGF and TF + mEMPs enhanced sprouting when compared with basal levels. Similar results were obtained with recombinant TF protein that also contains flTF ( Figure VII Matrigel plugs contain control solvent (PBS); vascular endothelial growth factor/ fibroblast growth factor 2 (basic) (VEGF/ bFGF) (50 ng/mL each); TF + mEMPs (100 pmol/L); or recombinant TF (100 pmol/L). B, Quantification of tube % covered area, branch points, and number of vessels per field. Values represent mean±SD from 6 animals for each group. Statistical analysis was performed by ANOVA followed by Tukey post hoc test (*P<0.05 and ***P<0.001 vs control cells). C, Western blots show TF, β1-integrin, Rac1, phospho-ERK1/2, ERK1/2, p-ETS1, ETS1, and chemokine (C-C motif) ligand 2 (CCL2) protein levels in skin tissue. To test the equal loading, the Western blots were reproved for β-actin. Histogram shows densitometry analysis of the average levels for total protein to β-actin; results are expressed as ±SEM. Statistical analysis was performed by ANOVA followed by Tukey post hoc test, **P<0.01 and ***P<0.001 vs control skin tissue and #P<0.01 and ###P<0.001 vs vascular endothelial growth factor/fibroblast growth factor 2 (basic) (VEGF/bFGF). resulted in abrogation of vessel outgrowth. Thus, exogenous TF requires β1-integrin ligation to trigger sprouting. In a second experimental approach, we examined whether TF + mEMPs could induce angiogenesis in vivo. Matrigel plugs were subcutaneously injected in nude mice. Plugs contained control buffer, VEGF/bFGF, TF + mEMPs, and recombinant TF protein. As shown in Figure 4A , top, when we injected a matrigel plug with control buffer, little vascularization was found in the skin around the plug. However, when we injected a plug with VEGF/bFGF, tissue surrounding the matrigel plug implants showed well-developed zones of neovascularization. This neovascularization effect in the tissue around the plugs was better developed in plugs with TF + mEMPs, showing thick main vessels, with many branches that generated secondary branches. Similar results were observed when recombinant TF protein was added in the matrigel. Quantification of area covered by capillaries and branching points ( Figure 4B ) gave highly significant increases in TF + mEMP-exposed animals. These results were confirmed by histology and blood vessels observation by von Willebrand factor-positive staining in the skin around to the plug (Figure 4A, bottom) . As shown in Figure VIII in the online-only Data Supplement, effects of TF + mEMPs were not mediated by VEGF/VEGFR. To evidence the role of TF in this new blood vessel formation, we determined TF, β1-integrin protein, Rac1, ERK1/2, and ETS1 protein levels in skin surrounding the plug ( Figure 4C ). Western blots show that TF was significantly increased in all situations except in control skin. Moreover, Figure IX in the online-only Data Supplement shows that skin tissue with recombinant TF-and VEGFmatrigel plugs shows soluble TF (rTF) protein expression, whereas skin tissue with TF + mEMPs-matrigel plugs only show flTF protein expression. TF expression was also accompanied by β1-integrin, Rac1 increases and ERK1/2 and ETS1 activation, with final increases in CCL2 protein levels ( Figure 4C ). Thrombin effect was also evaluated and excluded ( Figure X in the online-only Data Supplement).These results indicate that TF + mEMPs are able to induce angiogenesis in vivo, with a significantly higher effect than VEGF/bFGF.
Local Administration of TF + mEMPs Stimulates Angiogenesis in Ischemic Mice Hind Limbs
The highly significant effects of TF + mEMPs in vitro and in vivo prompted us to investigate in a therapeutic fashion whether TF + mEMPs could induce ischemic tissue reperfusion. We studied the effects of TF + mEMPs administration on neovessel formation in ischemic hind limbs after femoral ligation in nude mice. One day after surgery (ligation of arteries), we injected PBS; 100 pmol/L recombinant TF protein, 100 pmol/L TF + mEMPS, 1×10 7 TF overexpressing human microvascular endothelial cell-1 cells, or 1×10 7 TF-silenced human microvascular endothelial cell-1 cells. Injections were administrated into 4 delivery sites in the ischemic area (25 μL for each site total volume of 100 μL). Although 16% of animals in the control group (PBS injection) had a Qi scale 33 of 4, in the TF + mEMP-treated group, no animal had ambulatory impairment. Macroscopic observation of mouse hind limbs at day 21 after ligation showed that TF + mEMPs were able to induce new vessel formation because new capillaries could be observed in the ischemic zone when compared with animals treated only with control buffer (Figure 5A, top) . To evaluate the appearance of mature complex new blood vessels, α-actin immunostaining for detecting microvessels with pericytes was performed. Confocal analysis demonstrated that TF + mEMPs significantly increased collateral capillary formation in hindlimb ischemia on day 21 (Figure 5A, bottom) . Finally, protein analysis revealed an activation of the TF signaling pathway within the ischemic hindlimb in the TF + mEMPs injection group ( Figure 5C ). Adduction muscle tissue from the enriched capillary zone was processed by Western blot. Administration of TF + mEMPs significantly promoted activation of TF signaling. The newly formed capillary area had upregulated β1-integrin, Rac1 levels, and ERK1/2 and ETS1 activation and finally CCL2 expression. Because TF-silenced cells are not able to generate TF-bearing mEMPs ( Figure IIC in the online-only Data Supplement), capillary formation and pathway activation were not affected by the administration of ECs TF − ( Figure 5 ).
Magnetic resonance angiography that measures patent functional vessels (with flowing blood) was then used to visualize the induced therapeutic angiogenesis and collateral vessel formation after hindlimb ischemia. Using 2D-time-offlight angiography, we observed that the number of visible collateral vessels was highly increased in animals treated with TF + mEMPs compared with untreated animals or those treated with mEMPs not positive for TF (TF − EMPs) after surgery ( Figure 6A ). Computer-assisted measurements of crosssectional area of perfused vasculature ( Figure 6B ) were made on transverse images from the 2D-time-of-flight angiography data sets using thresholding. After 21 days of total ligation (20 days of treatment), the mean total cross-sectional area of perfused vasculature in the ligated limb was 2.5-fold higher in TF + mEMPs than that of the PBS or TF − EMP-treated group ( Figure 6C ).
Together, these results indicated that the administration of TF + mEMPs induce signaling pathways that contributed to postischemic hindlimb neovascularization and collateral competent vessel formation. TF + mEMPs bind to β1-integrin that signals through Rac1, ERK1/2, and ETS1-producing CCL2 that then recruits pericytes toward ECs forming mature-stable neovessels with flowing blood.
Animals were tested for tentative activation of systemic coagulation but alterations were not evidenced. Clotting timeextrinsic coagulation pathway was 61±3 s in animals treated with TF + mEMPs versus 58±6 s in control animals, and clotting time-intrinsic coagulation pathway was 223±8 s in animals treated with TF + mEMPs versus 229±7.5 s in control animals.
Discussion
TF has now a well-recognized role because a signaling molecule involved in the regulation of angiogenesis. 24, 34 Different studies have demonstrated the ability of TF to interact with cell surface integrins, inducing cell signaling pathway activation. 19, 32, 35 This is the first report on the direct action of TF transported in microparticles derived from microvascular endothelium on angiogenesis, and in collateral vessel formation in ischemic limbs. Our data indicate that TF released by activated mECs in the form of microparticles is able to adhere to other mECs in a β1dependent fashion and increase endothelial tube-like formation through β1-integrin, Rac1, ERK1/2, and ETS1 activation and finally CCL2 expression. In a hindlimb ischemia model, the administration of TF + mEMPs are able to increase functional new vessels and collaterals in vivo.
Depending on the cell type, cell surface composition, and concentration, microparticles have been described with capacity to increase or decrease angiogenesis. 5, 36, 37 Whether mECs are able to release TF-bearing mEMPs may be dependent on the trigger of mEC activation. In our study, we have demonstrated that the mECs activated to induce angiotube formation release microparticles that are rich in TF, which further enforce neovessel formation. These results indicated that TF plays a role not only as a receptor but also as a effector. Normally, microparticles rich in TF derived from quiescent ECs have been linked to procoagulant activity. Moreover, TF-rich microparticles have been described in diseases associated with thrombotic complications, such as sepsis, 38 diabetes mellitus, 39 and particularly in cancer. 40, 41 TF-bearing microparticles may be released by tumor cells and consequently are considered an important link between cancer and thrombosis. 42 Therefore, the cell type releasing microparticles seems to regulate the function of these shed vesicles, depending on both cell nature and cell activation status. Ettelaie et al 43 demonstrated that high glucose and advanced glycation end-products induce TF-bearing MPs in human renal mesenchymal cells but not in human dermal endothelial cell. Here, we show that TF + mEMPs release by mECs forming angiotubes have a high angiogenic activity in vitro and in vivo. It has been described that exogenous TF induces several cellular effects, such as the induction of proliferation, migration, and finally tube formation. 44, 45 Our results shown that the proangiogenic activated mECs are able to release TF-bearing mEMPs, which drive other mECs and pericytes to increase new vessel formation.
Neovascularization can be considered as the culmination of several steps: first, degradation of extracellular matrix, migration, adhesion, and proliferation of ECs; second, formation of a new 3D tube, which then lengthens from its tip and circulation is re-established; and finally, recruitment of SMCs that must migrate as well, and adhere to the newly formed EC capillaries. The initial stimulus that leads SMCs to migrate is not well-understood. Our previous work showed that microvascular endothelial TF induces CCL2 expression and secretion that recruit SMC toward ECs by an intracrine signaling activation process. 22 Here, we show that mECs in addition to microparticles release exerts a paracrine regulation to induce angiotube formation.
Proangiogenic activity of TF-bearing mEMPs was unclear, especially in the context in which the signaling activity of TF seems to be linked to its cytoplasmic domain, 46 which is probably sequestered within the microparticles. Some studies have demonstrated that cell surface TF signals through α3β1integrin and α6β1-integrin in ECs. 19 Moreover, alternatively spliced TF also interact with αvβ1-integrin and α6β1-integrin on ECs resulting in increase migration and tube formation, independently of FVIIa. 35 Recently, it has been shown that alternatively spliced TF promotes breast cancer progression in a β1-integrin-dependent manner. 47 In this regard, Collier and Ettelaie 32 demonstrated that TF microparticles interact with cell surface β1-integrin in ECs to induce proliferation. Our findings further show that TF-bearing mEMPs interact with ECs through interaction with β1-integrin to stimulate angiotube formation.
Integrins are transmembrane receptors that link proteins from outside the cell to cytoskeletal proteins and signaling pathways inside the cell. 48 To investigate the signal transduction pathways involved in TF+EMPs/β1-integrin interaction, we studied the Rac1 protein. Rac1 is a small signaling G protein, member of the Rac subfamily of the Rho GTPases family. In this study, we show that TF-bearing mEMPs induce mECs migration by binding β1-integrin and Rac1 and ERK1/2 activation. β1-integrin signals through Rac1, which plays a key role in connecting various cell surface receptors to biochemical pathways inducing cell motility and gene expression. 49 Previous studies from our group demonstrated that endogenous TF in SMC promotes migration through Rac1, 20 and Collier et al 32 demonstrated that TF-bearing EMPs stimulate endothelial proliferation through ERK1/2 and require β1-integrin interaction. Previously, we have shown that endogenous TF signals through AKT activating Raf/ERK and ETS1 signaling to induce endothelial microvessels formation partially independent of PAR2. 24 It has been demonstrated that flTF in complex with factor VIIa promotes PAR2-dependent angiogenesis; however, alternatively spliced TF enhances angiogenesis independent of downstream coagulation factors or PAR2 activation and it is dependent on integrins. 35 In our experiments, we have used microparticles containing flTF, derived from flTF overexpressing ECs; however, similar results were obtained when we used recombinant TF protein because recombinant TF contains soluble TF and flTF probably generated during the production of the recombinant protein ( Figure VII in the online-only Data Supplement). In vivo, TF-bearing mEMPs may be foes or friends. Procoagulant activity of microparticles has been reported in atherosclerotic plaques 28 and in patients with acute coronary syndrome. 30 They are considered as biomarkers of bad prognosis in cardiovascular disease; however, here we demonstrated that TF-bearing microparticles released by mECs programmed to form angiotubes, isolated and therapeutically administrated to ischemic tissue are able to repair the consequences of arterial occlusion and promote postischemic revascularization. In conclusion, our data indicate that TF-bearing mEMPs can serve as a novel therapeutic intervention for the treatment of critical limb ischemia. TF-bearing mEMPs through β1-integrin signaling and finally CCL2 expression in skeletal muscles enhance reperfusion with increased blood flow and capillary formation around the ischemic zone. This capacity of TF to increase neovascularization leading to wound-healing and repair of ischemic injury by switching-on formation of collaterals is an attractive concept that requires translational validation in more complex preclinical models.
